Strength in numbers - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Strength in numbers

Pharmaceutical Technology Europe
Volume 21, Issue 9

Fedra Pavlou
Merger, union, alliance, partnership, collaboration: five words that ultimately suggest the strengthening of something. Every company, no matter how large or small, must undertake at least one of these strategies to secure its longevity.

Indeed, no one can escape the frenzy of activity that has been taking place in the pharmaceutical industry lately. Such unions have, of course, been commonplace; however, it's been quite interesting to see pharma's response to the threats it currently faces, including, amongst others, the economic downturn, dry development pipelines and generic competition. The reaction of these already giant corporations has been to form alliances to grow an existing division, to diversify, to shed an underperforming unit, to secure a solid pipeline, and so on. Whatever the secondary reason, the primary reason has always been to secure growth, to strengthen, to improve and to survive.

At Pharmaceutical Technology Europe, we too have undertaken such a union; we have united with our US colleagues at Pharmaceutical Technology to bring our readers a tool that we believe is the best online resource for pharmaceutical manufacturing professionals. We hope that you agree with us!

Launched last month, the new covers developments from around the world in formulation, outsourcing, drug delivery, ingredients, regulatory, testing, packaging and IT. As well as providing news and analysis, the site allows you to interact with us and your peers on Pharma Tech Talk, access archives of peer-reviewed content and features, take part in surveys and polls, search suppliers, read interviews with industry leaders, search for careers, watch webcasts, listen to podcasts, and access our significant library of white papers. I could go on, but I hope all of these are reason enough to entice you to visit our brand new website and to keep coming back!

I would welcome your comments and suggestions on the new so please do feel free to email me with your thoughts. After all, this website is for you.

Many thanks and best wishes,


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
Source: Pharmaceutical Technology Europe,
Click here